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Abstract
Introduction: Cigarette smoke is a profound pro-inflammatory stimulus that contributes to acute lung injuries and to
chronic lung disease including COPD (emphysema and chronic bronchitis). Until recently, it was assumed that resolution of
inflammation was a passive process that occurred once the inflammatory stimulus was removed. It is now recognized that
resolution of inflammation is a bioactive process, mediated by specialized lipid mediators, and that normal homeostasis is
maintained by a balance between pro-inflammatory and pro-resolving pathways. These novel small lipid mediators,
including the resolvins, protectins and maresins, are bioactive products mainly derived from dietary omega-3 and omega-6
polyunsaturated fatty acids (PUFA). We hypothesize that resolvin D1 (RvD1) has potent anti-inflammatory and pro-resolving
effects in a model of cigarette smoke-induced lung inflammation.
Methods: Primary human lung fibroblasts, small airway epithelial cells and blood monocytes were treated with IL-1b or
cigarette smoke extract in combination with RvD1 in vitro, production of pro-inflammatory mediators was measured. Mice
were exposed to dilute mainstream cigarette smoke and treated with RvD1 either concurrently with smoke or after smoking
cessation. The effects on lung inflammation and lung macrophage populations were assessed.
Results: RvD1 suppressed production of pro-inflammatory mediators by primary human cells in a dose-dependent manner.
Treatment of mice with RvD1 concurrently with cigarette smoke exposure significantly reduced neutrophilic lung
inflammation and production of pro-inflammatory cytokines, while upregulating the anti-inflammatory cytokine IL-10. RvD1
promoted differentiation of alternatively activated (M2) macrophages and neutrophil efferocytosis. RvD1 also accelerated
the resolution of lung inflammation when given after the final smoke exposure.
Conclusions: RvD1 has potent anti-inflammatory and pro-resolving effects in cells and mice exposed to cigarette smoke.
Resolvins have strong potential as a novel therapeutic approach to resolve lung injury caused by smoke and pulmonary
toxicants.
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Introduction
Cigarette smoke is a potent pro-inflammatory stimulus and a
major risk factor for many diseases having an inflammatory
component including cardiovascular disease, stroke and lung
cancer. Tobacco smoking is the primary risk factor for chronic
obstructive pulmonary disease (COPD) emphysema and chronic
bronchitis, and is the fifth leading cause of death worldwide [1].
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e58258Inflammation is a key factor contributing to lung diseases caused
by smoking. Until recently, it was assumed that resolution of
inflammation was a passive process that occurred once the
inflammatory stimulus was removed. It is now recognized that
resolution of inflammation is a bioactive process, mediated by
specialized lipid mediators, and that normal homeostasis is
maintained by a balance between pro-inflammatory and pro-
resolving pathways [2].
Several classes of pro-resolving mediators have been identified,
including resolvins, protectins, and maresins [3]. These specialized
lipid mediators are derived via enzymatic processing from dietary
omega-3 polyunsaturated fatty acids (v-3-PUFAs), including
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Several of these mediators have anti-inflammatory and pro-
resolving activity in pre-clinical disease models such as peritonitis
[4], colitis [5], dermal inflammation [6] and asthma [7]. Protectin
D1 and resolvin E1 reduce airway hyperresponsiveness and
inflammation in animal models of pneumonia and asthma [8,9].
Furthermore, diets rich in v-3-PUFAs appear to have beneficial
effects in lung diseases such as COPD and asthma [10,11]. These
findings support the idea that pro-resolving lipid mediators in the
lung could play a key role in controlling inflammation and return
to homeostasis.
Many cell types in the lung respond to cigarette smoke by
producing pro-inflammatory mediators. We have previously
reported that lung fibroblasts play a significant role in orchestrat-
ing inflammatory responses, and respond to cigarette smoke by
increasing expression of COX-2 and production of pro-inflam-
matory prostaglandins and other pro-inflammatory mediators
[12]. Macrophages also respond to cigarette smoke by producing
pro-inflammatory mediators [13]. These pro-inflammatory medi-
ators recruit immune cells such as neutrophils and additional
macrophages and stimulate nearby epithelial and endothelial cells
resulting in inflammation and tissue damage.
Interestingly, lung macrophages play a dual role in the response
to cigarette smoke. Classically activated, so-called M1 macro-
phages, express inducible nitric oxide synthase (iNOS) and tumor
necrosis factor-a (TNF-a), and are generally thought to be pro-
inflammatory. Recent research has demonstrated the importance
of alternatively activated, or M2 macrophages, which are activated
by Th2 cytokines such as IL-4 and IL-13, or the immunosup-
pressive cytokines IL-10 and TGF-b [14]. M2 lung macrophages
play an essential role in the clearance of inhaled particles,
pathogens and apoptotic cells including neutrophils (efferocytosis)
[15–17]. Studies have shown that cigarette smoking is associated
with defects in lung macrophage function [18] and macrophages
isolated from COPD patients had a reduced ability to clear
apoptotic neutrophils [19,20], suggesting that macrophage defects
are a key pathogenic feature of the disease. Thus, fibroblasts and
macrophages are not only useful as in vitro models to evaluate new
anti-inflammatory and pro-resolving molecules, but are highly
relevant to in vivo therapeutic outcomes.
Resolvin D1 (RvD1, 7S,8R,17S-trihydroxy-4Z,9E,11E,13-
Z,15E,19Z-docosahexaenoic acid) is a derivative of DHA [4] with
potent anti-inflammatory and pro-resolving properties. The 17R
epimer of RvD1 (17R-RvD1) is produced via an alternative
biochemical pathway but has similar in vitro and in vivo activity and
uses the same receptors as RvD1. Notably, 17R-RvD1 is resistant
to inactivation by the endogenous enzyme 15-prostaglandin
dehydrogenase/eicosanoid oxidoreductase (15-PDGH) and poten-
tially has a longer duration of effect in vivo [21]. RvD1 and 17R-
RvD1 inhibit neutrophilic inflammation and promote efferocytosis
in several disease models [22–25]. RvD1 also promotes M2
differentiation in mouse models of peritonitis and obesity-induced
adipose tissue inflammation and insulin resistance [26,27].
Here, we investigated the impact of RvD1 on the production of
pro-inflammatory mediators by human primary lung fibroblasts,
epithelial cells and blood-derived macrophages stimulated with
cigarette smoke extract or IL-1b and in a mouse model of acute
cigarette smoke (CS)-induced lung inflammation. RvD1 has potent
anti-inflammatory effects in vitro and in vivo, and inhibition of
inflammation is associated with increased differentiation and
function of M2 lung macrophages. These results suggest that
RvD1 may be a potential new therapeutic for cigarette smoke-
induced lung injury and other inflammatory lung diseases.
Materials and Methods
Ethics Statement
All animal procedures were approved and supervised by the
University of Rochester University Committee on Animal
Resources (UCAR permit number 2007-127). For euthanasia,
mice were anesthetized with an intraperitoneal injection of avertin
(2,2,2-tribromoethanol, 250 mg/kg), followed by exsanguination
and removal of the lungs for analysis, and all efforts were made to
minimize suffering. Primary human lung fibroblasts were derived
from culture of tissue explants following biopsy specimens from
patients undergoing lung resection surgery for hamartoma, a
benign lung tumor. The fibroblasts were grown tissue from
anatomically normal areas of the specimen distal to the lesion.
Human blood monocytes were isolated from peripheral blood
collected from healthy donors. All blood and tissue donors
provided informed written consent as described in study protocols
approved by the University of Rochester Institutional Review
Board and conforming to the Helsinki Declarations. Primary
human small airway epithelial cell cultures were obtained from a
commercial source.
Cell Culture and Analysis of Pro-inflammatory Mediators
Primary human lung fibroblast cultures were established from
lung tissue explants as previously described [28] and used at early
passage (P3–P9). Primary human small airway epithelial cells
(SAEC) were purchased from a commercial vendor (Lonza,
Allendale, NJ) and cultured in small airway epithelial cell growth
medium supplemented as recommended by the supplier. Blood
monocytes were cultured in RPMI 1640 as described [29].
Serum starvation was performed to reduce the effect of serum
components on induction of cyclooxygenase-2 (COX-2) and other
inflammatory mediators. Aqueous cigarette smoke extract (CSE)
was prepared as previously described [30]. Briefly, smoke from
two reference cigarettes (1R3F, University of Kentucky) was
bubbled through 20 ml of serum free medium. This is arbitrarily
defined as ‘‘100% CSE.’’ To adjust for batch-to-batch variation,
the average absorbance at 320 nm for several batches of CSE was
measured and determined to be 0.65 absorbance units. Thereafter,
CSE preparations are diluted as needed so that 100% CSE has a
standard OD320=0.65. The pH of the CSE is adjusted to 7.4, and
the CSE is then sterile filtered with a 0.45-mm filter (25-mm
Acrodisc; Pall, Ann Arbor, MI). CSE was freshly prepared for each
experiment and diluted with serum-free MEM immediately before
use. Cultures were pre-treated with 10 nM, 100 nM or 1 mM
RvD1 or vehicle control solution (0.1% ethanol) for 24 hours prior
to the addition of 1% or 5%CSE or 1 ng/ml IL-1b (R&D
Systems, Minneapolis, MN) for an additional 24 hours. As the
RvD1 was supplied in ethanol, vehicle control cultures were
treated with the same final concentration of ethanol (0.1%).
Inflammatory mediators were determined in cell culture superna-
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by western blotting using an antibody specific for COX-2
(Cayman Chemical, Ann Arbor, MI) and or GAPDH (Abcam,
Cambridge, MA), which serves as a normalization control.
Cigarette Smoke Exposures
Adult female C57BL/6J mice were purchased from The
Jackson Laboratory (Bar Harbor, ME) and used at 8–12 weeks
of age. Mice were exposed to dilute mainstream cigarette smoke
(CS) for 1 hour, twice per day, for 3 days, as described [31].
Resolvin D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-
docosahexaenoic acid) and 17R-RvD1 (7S,8R,17R-trihydroxy-
4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) were obtained
from Cayman Chemical. In the pre-treatment exposure model,
100 ng RvD1 in 40 ml saline was given by oropharyngeal
aspiration on day 0, and 1 hour prior to the first smoke exposure
on days 1, 2 and 3. Control animals were treated with saline
vehicle. Smoke exposures were quantified by determining total
suspended particulate matter (TSP) by gravimetric sampling. The
smoke concentration was set at a nominal value of 450 mg/m
3
TSP by adjusting the number of cigarettes loaded onto the
carousel and the flow rate of the dilution air. Control animals were
exposed to filtered air in identical equipment on the same
schedule. Mice were euthanized on day 4 and cells and tissues
were harvested for analysis. To analyze the resolution of active
inflammation, mice were exposed to CS for 2 hours per day on
days 1–3. On day 3, after the final smoke exposure, and on days 4
and 5, the mice were treated with vehicle or 100 ng RvD1 by
oropharyngeal aspiration as described. The mice were euthanized
and analyzed on day 4 and 6.
Analysis of Bronchoalveolar Lavage Fluid (BALF) and
Lung Tissues
BALF was collected from smoke-exposed mice and analyzed as
previously described [31]. The right lung was frozen in liquid
nitrogen for later analysis. Total protein in BALF was determined
by the bicinchoninic acid (BCA) colorimetric assay (Thermo
Scientific, Rockford, IL). The right lung was homogenized in
RIPA buffer as described [32], and lung proteins were analyzed
for expression of COX-2 (Clone CX229, Cayman Chemical, Ann
Arbor, MI), Arg-1 (H-52; Santa Cruz Biotechnologies, Santa
Cruz, CA) and total actin (CP01; Calbiochem, San Diego) by
Western blotting. In some experiments, the lungs were inflated
and fixed with 10% neutral buffered formalin without undergoing
lavage. Tissues were embedded with paraffin, sectioned (5 mm),
and stained with hematoxylin and eosin (H&E).
Immunohistochemistry
Lung-infiltrating neutrophils were stained with rat anti-mouse
Ly-6B.2 (MCA771GA, Serotec, Oxford, UK) and HRP-conju-
gated goat anti-rat antibodies, followed by visualization with AEC
chromagen (Vector Lab, Burlingame, CA) and hematoxylin
counter staining.
Analysis of Cytokines and Chemokines
Human IL-6, IL-8 and MCP-1 were measured in cell culture
media by commercial ELISA according to the manufacturer’s
instructions (R&D Systems). Prostaglandin E2 (PGE2) was
measured by competitive enzyme immunoassay (EIA) using
commercially available reagents as described(Cayman Chemical)
[33]. Mouse cytokines and chemokines were measured in BALF
by ELISA (MIP-2, KC; R&D Systems) or by bead-based multiplex
analysis of lung homogenates (IL-1b, IL-6, MCP-1, IFN-c and IL-
10; Millipore, Billerica, MA) using a Luminex FlexMAP3D
instrument (Luminex, Austin, TX). Results are expressed as
picograms of cytokine per milligram of total protein in the
homogenate.
Assessment of Macrophage Phagocytosis of Neutrophils
Lungs were harvested from mice exposed to smoke and treated
with RvD1 as described above. One lobe was digested with
collagenase and a single cell suspension was prepared. Total lung
macrophages were isolated by CD11b magnetic bead separation
(Miltenyi Biotech, Cambridge, MA) [34]. The cells were then
labeled with FITC-conjugated anti-mouse F4/80 antibody (BM8;
Invitrogen; Camarillo, CA) for 30 minutes, then fixed with 4% of
paraformaldehyde and permeabilized with 0.1% Triton X-100.
Ingested neutrophils were labeled by staining permeabilized cells
with PE-conjugated anti-mouse Gr-1 (RB6-8C5; BD Pharmingen)
antibodies for 30 minutes and analyzed by flow cytometry
(FACSCanto II; BD Biosciences, San Jose, CA). Forward and
side scatter was first used to exclude doublets or macrophages that
are attached to but did not fully engulf neutrophils. Cells were then
gated based on F4/80 positive staining. The frequency of cells that
are F4/80 and GR-1 double positive was then quantified.
Macrophage Phagocytic Activity in vitro
Alveolar macrophages were harvested from naı ¨ve mice by
lavage in PBS buffer containing 0.6 mM EDTA and glucose
(0.1%). Macrophages were activated with 1 ng/ml IL-1b for 30
minutes and then incubated with RvD1 (100 nM in 0.1% ethanol)
or 0.1% ethanol alone for an additional 30 minutes before the
addition of a 10-fold excess of FITC-conjugated latex micro-
spheres for 1 hour. Uptake of FITC-labeled latex microspheres
was measured by flow cytometry (FACSCanto II, BD Biosciences).
Characterization of Alveolar Macrophages
Lungs were lavaged extensively (0.5 ml for 5–10 times) with
PBS containing 0.1% glucose to collect lung macrophages.
Collected cell suspensions were enriched for macrophage by
adherence on tissue culture-treated plastic dishes for 1 hour in
minimum essential medium (MEM; Gibco, Camarillo, CA)
containing 10% fetal bovine serum. Non-adherent cells were
discarded by gently washing twice with PBS. RNA was extracted
from the enriched adherent macrophages by RNeasy kit according
to manufacturer’s instructions (Qiagen; Valencia, CA). RNA
(1 mg) was reverse-transcribed using the iScript cDNA synthesis
Kit (BioRad; Hercules, CA) and the cDNA was subjected to
quantitative real-time PCR using SYBR GreenER in a BioRad
iQ5 cycler. In brief, a 20 ml mixture was used containing 10 mli Q
SYBR Green Supermix, 0.5 ml forward and reverse primer, 7.5 ml
sterile water, and 2 ml of the 1:5 diluted cDNA template. The real-
time PCR was performed under the following conditions: 1 cycle
at 95uC for 3 minutes, then 40 cycles at 95uC for 10 seconds, 55uC
for 30 seconds, 95uC for 1 minute followed by 55uC for 1 min.
The intron-spanning primers were designed by using sequence
information from the NCBI database. The Ct values were
normalized to the endogenous control (18sRNA). Primer sequenc-




mArg1-R: 59- CAGATATGCAGGCAGGGAGTCACC -39
mMrc1-F: 59- CTCTGTTCAGCTATTGGACGC -39
mMrc1-R: 59- CGGAATTTCTGGGATTCAGCTTC-39
miNOS-F: 59- GTTCTCAGCCCAACAATACAAGA -39
miNOS-R: 59- GTGGACGGGTCGATGTCAC -39
RvD1 Resolves Cigarette Smoke Inflammation
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mTNFa -R: 59- TTGGTGGTTTGTGAGTGTGAG -39
mIL-10-F: 59- GCTCTTACTGACTGGCATGAG -39
mIL-10-R:59- CGCAGCTCTAGGAGCATGTG -39
Statistical Analysis
Results are reported as the mean 6 SEM or mean 6 SD as
indicated. T-test (two tailed) or one-way and two-way analysis of
variance (ANOVA) with Bonferroni multiple comparisons were
performed using GraphPad Prism version 5.0d for Mac (Graph-
Pad Software, La Jolla California USA, www.graphpad.com). A P
value ,0.05 was considered significant.
Results
RvD1 Inhibits IL-1b-induced and CSE-induced Cytokine
and Chemokine Production in Primary Human Lung
Fibroblasts
Lung fibroblasts produce many pro-inflammatory molecules
and amplify inflammatory cascades following exposure to pro-
inflammatory insults including cigarette smoke and IL-1b [35]. To
evaluate the ability of RvD1 to suppress inflammatory signaling in
lung fibroblasts, primary human lung fibroblasts were pre-treated
for 24 hours with the indicated concentrations of RvD1 then
stimulated with cigarette smoke extract (CSE) or IL-1b for an
additional 24 hours. IL-1b strongly induced production of pro-
inflammatory mediators including IL-6, IL-8, MCP-1 and PGE2
(Figure 1). RvD1 significantly inhibited the production of MCP-1
and PGE2 at 100 nM, and production of IL-6, IL-8, MCP-1 and
PGE2 at 1000 nM. CSE also induced these pro-inflammatory
mediators in human lung fibroblasts, although at lower levels than
IL-1b. IL-6, IL-8, MCP-1 and PGE2 were significantly attenuated
by RvD1 treatment (Figure 1, panels E, F, G and H). The pro-
inflammatory enzyme COX-2 is responsible for PGE2 production
and is elevated in a variety of inflammatory pulmonary diseases
include COPD [36]. IL-1b and CSE both induced COX-2
expression in human lung fibroblasts. Exposure to RvD1
(1000 nM) significantly attenuated COX-2 expression (Figure 1I),
suggesting a potent anti-inflammatory function for RvD1 in
human lung fibroblasts.
RvD1 Inhibits Production of Inflammatory Mediators in
Monocytes and Lung Epithelial Cells
Macrophages and epithelial cells are important sources of
inflammatory cytokines in cigarette smoke-exposed lungs. To
evaluate the effect of RvD1 on these cell types, human primary
small airway epithelial cells (SAECs) and blood-derived monocytes
were pre-treated with the indicated concentrations of RvD1 before
the addition of IL-1b or CSE for an additional 24 hours. RvD1
significantly dampened production of IL-6 and IL-8 from SAEC
treated with IL-1b (Figure 2A–B). In our hands, IL-1b did not
stimulate release of PGE2, and CSE did not stimulate production
of IL-6 or IL-8 from SAEC (data not shown). Both IL-1b and CSE
induced expression of IL-6 and IL-8 from human monocytes. A
one-hour pre-treatment with RvD1 significantly inhibited produc-
tion of IL-6 and IL-8 in a dose-dependent manner (Figure 2C–F).
In these experiments the monocytes produced high background
levels of PGE2 which was not significantly increased further by
CSE, therefore an effect of RvD1 on PGE2 production could not
be determined (data not shown). Interestingly, monocytes were
more resistant to CSE than fibroblasts and required treatment
with 5% CSE to induce a strong response, but were more sensitive
to RvD1, with potent inhibition seen at 10 nM (Figure 2C–F).
RvD1 Attenuates Cigarette Smoke-induced Inflammation
in vivo
Based on our in vitro results, we hypothesized that administra-
tion of RvD1 would attenuate cigarette smoke-induced acute lung
inflammation in vivo. Mice received 100 ng RvD1 by inhalation 1
hour prior to cigarette smoke exposure daily for 3 days. On day 4,
the mice were euthanized, bronchoalveolar lavage fluid (BALF)
was collected, and inflammation was evaluated by differential cell
counting. Cigarette smoke (CS) exposure induced significant
increases in total BAL cells, neutrophils and lymphocytes, but
not macrophages or eosinophils (Figure 3), consistent with prior
experience with this model [37,38]. The increase in total cell
number is almost entirely due to recruitment of neutrophils
(Figure 3C). CS-exposed mice pre-treated with RvD1 had
significantly fewer neutrophils in BALF compared to vehicle-
treated controls, expressed either as neutrophil number (Figure 3C)
or percentage (Figure 3F) of total cells. There was no change in the
absolute numbers of macrophages between CS and CS+RvD1-
treated mice (Figure 3B). As noted, RvD1 had no significant
impact on the numbers of BAL lymphocytes (Figure 3D) and
eosinophils (Figure 3E). Interestingly, while total macrophage
numbers were not changed, there was a significant increase in the
percentage of macrophages in the BALF with RvD1 treatment
(Figure 3F).
RvD1 Reduces Cigarette Smoke-induced Neutrophilic
Lung Inflammation
The location of infiltrating neutrophils in lung tissues was
determined by immunohistochemical staining for the neutrophil
specific marker Ly-6B.2. In RvD1-treated, air-expose lung,
neutrophils were sparsely detected (Figure 4A and 4B). Acute
smoke exposure causes accumulation of neutrophils around vessels
(v), airways (a) (Figure 4C, arrows) and in the parenchyma
(Figure 4D), with neutrophils prominent in the interstitial spaces
(Figure 4D, arrows) and the alveoli (Figure 4D, solid triangles).
RvD1 reduces the appearance of CS-induced neutrophils in lung
tissue consistent with the results of differential cell counts in BALF
that RvD1 reduces neutrophil accumulation in the lung.
RvD1 Decreases Production of Pro-inflammatory
Mediators
Levels of pro-inflammatory cytokine and chemokine were
determined in BALF and lung homogenates of smoke-exposed
mice. Total protein in BALF, an indication of vascular leakage and
edema, was also increased with CS exposure and significantly
reduced with RvD1 treatment (Figure 5A). Acute cigarette smoke
exposure induces the expression of neutrophil chemoattractants
KC and MIP-2, which was significantly inhibited by RvD1
(Figure 5, panels B and C). CS exposure also resulted in increased
production of pro-inflammatory cytokines including IL-1b, IL-6,
and MCP-1. RvD1 markedly decreased IL-1b and IL-6 but not
MCP-1 (Figure 5, panels D-F). IFN-c content was increased with
CS and decreased with CS+RvD1 treatment, however the
difference was not significant (Figure 5G). Interestingly, the anti-
inflammatory cytokine IL-10 was significantly increased in lungs
from CS-exposed mice pre-treated with RvD1 (Figure 5H). We
also evaluated expression of COX-2 protein and PGE2 levels in
lung homogenates, which showed results consistent with our in vitro
findings that CS increases PGE2 production and COX-2
expression, which is strongly inhibited by RvD1 (Figure 5I and
5J, respectively).
RvD1 Resolves Cigarette Smoke Inflammation
PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e58258Figure 1. RvD1 inhibits IL-1b-induced and CSE-induced cytokine and chemokine production from primary human lung fibroblasts.
Primary human lung fibroblasts were pre-treated with the indicated concentrations of RvD1 for 24 hours then stimulated with IL-1b (1 ng/ml) or
cigarette smoke extract (CSE, 1%) for an additional 24 hours. Culture media from IL-1b-treated cells (A–D) or CSE-treated cells (E–H) were subjected
to ELISA and EIA to detect various pro-inflammatory mediators as described in the Methods. Data shown are mean 6 SD for n=4 replicate cultures,
from one representative experiment of 3 performed. COX-2 and GAPDH expression (I) were determined in cell lysates by Western blotting. Blots
shown are representative of three independent experiments, and the lanes were run non-contiguously on the same gel. ***P,0.001, **p,0.01
*P,0.05 compared to IL-1b-treated or CSE-treated cultures without RvD1,
###P,0.001 versus vehicle-treated control cultures by one-way ANOVA
with Bonferroni post-tests.
doi:10.1371/journal.pone.0058258.g001
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Inflammation Induced by CS Exposure
Resolvins are reported to be pro-resolving as well as anti-
inflammatory [39]. To evaluate whether resolvins could accelerate
the resolution of CS-induced inflammation, we exposed mice to
CS for 3 days, and initiated resolvin treatment after the final
smoke exposure. For these experiments, we used the 17R epimer
of RvD1 (17R-RvD1) as it is less susceptible to in vivo inactivation
[4]. RvD1 and 17R-RvD1 bind the same receptor and have
similar activities in vitro [21]. Mice were euthanized on day 4 (after
a single 17R-RvD1 treatment on day 3) or day 6 (after receiving
17R-RvD1 on days 3, 4 and 5). A single dose of 17R-RvD1
accelerated the resolution of acute CS-induced inflammation, with
significant reductions in total BAL cells, macrophages and
neutrophils on day 4 (Figure 6, panels A, B and C). Although
the number of inflammatory cells was significantly reduced by
17R-RvD1, the percentages of neutrophils and macrophages did
not significantly change, as the number of macrophages,
neutrophils, and total cell numbers were reduced together
(Figure 6E, F). Inflammation on day 6 was also reduced with
17R-RvD1, although less dramatically than on day 4. 17R-RvD1
also significantly reduced production of the pro-inflammatory
cytokine IL-6 (Figure 6F), neutrophil chemokines KC and MIP-2
(Figure 6G and H, respectively) and PGE2 (Figure 6I).
Figure 2. RvD1 inhibits IL-1b and CSE-induced cytokine production from primary human small airway epithelial cells and
monocytes. Primary SAEC (A–B) were pre-treated with indicated concentrations of RvD1 for 24 hours then stimulated with IL-1b (1 ng/ml) for an
additional 24 hours. Culture media was collected and levels of IL-6 (A) and IL-8 (B) were determined by ELISA. Data shown are mean 6 SD of triplicate
cultures, from one representative experiment of 3 performed. Blood-derived monocytes (C–F) were pre-treated with indicated concentrations of
RvD1 for 24 hours then stimulated with IL-1b (1 ng/ml) or CSE (5%) for an additional 24 hours. Culture media was collected and levels of IL-6 (C, E)
and IL-8 (D, F) were determined by ELISA. Data shown are mean 6 SEM for three individual donors.
##p,0.01,
###p,0.001 compared to vehicle-
treated control cultures. **p,0.01, ***p,0.001 compared to IL-1b or CSE without RvD1, using one-way ANOVA with Bonferroni post-tests.
doi:10.1371/journal.pone.0058258.g002
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PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e58258Figure 3. RvD1 attenuates CS-induced inflammation in vivo. Mice were treated with 100 ng RvD1 (grey bars) or saline vehicle (Veh, black bars)
by inhalation 1 hour prior to cigarette smoke, daily for 3 days. Mice were euthanized at day 4, and differential cell counts were performed on BALF
cells. Total cell number (A), number of macrophages (B), neutrophils (C), lymphocytes (D), eosinophils (E) and percentage of macrophages and
neutrophils (F) are reported. Data are shown as mean 6 SEM for n =6–7 mice per group from one of 3 independent experiments. ***P,0.001, versus
smoke-exposed mice by two-way ANOVA with Bonferroni post-tests.
###P,0.001, versus air-exposed control mice by one-way ANOVA with
Bonferroni post-tests.
doi:10.1371/journal.pone.0058258.g003
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in vitro
We hypothesized that one mechanism by which RvD1
promotes resolution of CS-induced inflammation is by increasing
the phagocytosis of neutrophils by lung macrophages. To
investigate this mechanism, lung macrophages were harvested
from CS-exposed mice, fixed and permeabilized, then co-stained
for the macrophage marker, F4/80, and the neutrophil marker
Gr-1. Treatment with RvD1 increased the percentage of F4/80
and Gr-1 double positive cells, suggesting that clearance of
apoptotic neutrophils is enhanced in the presence of RvD1
(Figure 7A). We also investigated whether RvD1 increased
macrophage phagocytosis ex vivo. Alveolar macrophages were
isolated from naı ¨ve mice and stimulated with IL-1b (1 ng/ml) for
30 minutes, followed by RvD1 or vehicle for and additional 1
hour. The phagocytic ability of the macrophages was assessed
using FITC-labeled latex beads and analyzed by flow cytometry.
RvD1 enhanced overall bead uptake by 59% (Figure 7, panel B
Figure 4. RvD1 reduces CS-induced neutrophilic lung inflammation. Lungs from mice that had not been lavaged were inflated and fixed
with neutral buffered formalin, and 5 mm paraffin sections were stained with a neutrophil-specific antibody (brown) and counter-stained with
hematoxylin. An occasional neutrophil was observed in air-exposed mice treated with RvD1 (A, B), similar to air-exposed mice treated with vehicle
(not shown). CS induces a neutrophilic inflammation around vessels and airways (C) and in the parenchyma (D), with neutrophils prominent in the
interstitial spaces (arrows) and the alveoli (solid triangles). RvD1 treatment reduces perivascular and peribronchial (E) as well as parenchymal (F)
accumulation of neutrophils. A, airway; v, vessel. Arrows, interstitial neutrophils; solid triangles, neutrophils in airspaces.
doi:10.1371/journal.pone.0058258.g004
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that had phagocytosed at least one bead, RvD1 also increased the
number of beads phagocytosed per cell, with a 220% increase in
the percentage of cells ingesting 3 and a 660% increase in the
percentage of cells ingesting 4 or more beads (Figure 7C).
Figure 5. RvD1 decreases production of pro-inflammatory mediators in BALF and total lung homogenate but increases IL-10. Total
protein (A) in BALF was measured by BCA assay. Neutrophil chemoattractants KC (B) and MIP-2 (C), IL-1b (D), IL-6 (E), MCP-1 (F), IFN-c (G), PGE2 (H)
and IL-10 (I) were determined in lung homogenates by multiplex assay or EIA and normalized to total protein concentration. N.D., not detected. Data
are shown as mean 6 SEM for n=6–8 mice per group and are representative of 3 independent experiments. *P,0.05, **P,0.01, ***P,0.001 versus
smoke-exposed mice by two-way ANOVA with Bonferroni post-tests.
###P,0.001 compared to air-exposed control mice by one-way ANOVA with
Bonferroni post-tests. Expression of COX-2 and total actin (J) were determined in whole lung homogenates by Western blotting using COX-2 and
total actin specific antibodies. Each lane represents an individual mouse.
doi:10.1371/journal.pone.0058258.g005
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PLOS ONE | www.plosone.org 9 March 2013 | Volume 8 | Issue 3 | e58258Figure 6. 17R-RvD1 promotes the resolution of acute lung inflammation induced by CS exposure. Mice were exposed to CS exposure on
days 1, 2 and 3. The mice received 100 ng 17R-RvD1 (grey bars) or saline vehicle (Veh, black bars) by inhalation on day 3 (1 hour after the last
cigarette smoke exposure), day 4 and day 5. Mice were euthanized at days 4 and 6 and differential cell counts were performed on BAL cells. Total cell
number (A), number of neutrophils (B), and macrophages (C), percentage of neutrophils (D) and macrophages (E) are reported. BALF was collected
and analyzed by ELISA or EIA for IL-6 (F), KC (G), MIP-2 (H) and PGE2 (I). Data are shown as mean 6 SEM for n =4–5 mice per group. N.D., not
detected. *P,0.05, **P,0.01 compared to Vehicle/Smoke mice by two-way ANOVA with Bonferroni post-tests.
doi:10.1371/journal.pone.0058258.g006
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Macrophages
Given the increased IL-10 production and increased phagocytic
activity seen with RvD1 treatment, we hypothesized that RvD1
drives macrophage polarization to an M2 phenotype. RvD1
increased protein levels of arginase I (Arg1), a marker of M2
macrophages, in total lung homogenates (Figure 8A). We also
extracted RNA from lung macrophages from mice exposed to air
or CS, with or without RvD1 treatment, and determined mRNA
levels by quantitative RT-PCR. In macrophages from air-exposed
mice, RvD1 induced the M2 genes Arg1, mannose receptor 1
(Mrc1) and IL-10 demonstrating that the number of M2
macrophages increased after RvD1 treatment in the absence of
inflammatory stimuli (Figure 8B–D). In CS-exposed mice, RvD1
significantly increased mRNA expression of Arg1, Mrc1 and IL-10
from alveolar macrophages compared to vehicle-treated CS-
exposed mice (Figure 8, panels B-D). RvD1 significantly reduced
mRNA expression of iNOS and TNF-a (Figure 8, panels E and F),
two mediators highly expressed in classically-activated (M1)
macrophages. Taken together, these results clearly demonstrate
that RvD1 significantly augments the polarization of alveolar
macrophages to the M2 phenotype.
Discussion
Human lungs are exposed daily to thousands of liters of air
containing numerous environmental insults and pro-inflammatory
stimuli including dust, pollen, mold, ozone and hydrocarbon
pollutants. Given this, regulating the balance between pro-
inflammatory and pro-resolving signaling pathways is crucial to
maintain normal lung homeostasis [39]. Cigarette smoke is a
powerful pro-inflammatory stimulus and a leading cause of lung,
cardiovascular and other diseases [1,15]. Resolvin D1 is a member
of a novel class of lipid mediators with anti-inflammatory and pro-
resolving functions [3]. Here, we report that RvD1 is a potent
inhibitor of cigarette smoke-induced pro-inflammatory signaling in
human lung cells in vitro and has potent anti-inflammatory and
pro-resolving properties in a mouse model of acute cigarette
smoke-induced lung inflammation.
We first investigated the response of primary cells to RvD1
in vitro. RvD1 significantly reduced inflammatory responses in
primary human lung fibroblasts and blood-derived monocytes
using both IL-1b and CSE as inflammatory stimuli, and from
human small airway epithelial cells stimulated with IL-1b
(Figures 1 and 2). We used IL-1b as a model stimulus because
we and others have shown that CS exposure upregulates IL-1b
levels in both mice and humans exposed to cigarette smoke
(Figure 4) [40]. Therefore, lung cells are likely exposed to IL-1b
following smoke exposure in vivo. Cigarette smoke extract is widely
used as an in vitro analog to inhalation of smoke but an exact
equivalence between in vitro and in vivo exposures can not be
determined [41]. It is interesting to note that RvD1 abolished IL-
1b-induced PGE2 production in lung fibroblasts and inhibited
PGE2 production in vivo. The role of PGE2 in regulating
inflammation is complex, as PGE2 has both pro-inflammatory
and pro-resolving properties. PGE2 is a potent neutrophil
chemokine, and is upregulated by cigarette smoke (Figure 5)
[12,42,43]. However, PGE2 also has anti-inflammatory properties
in neutrophils, and is involved in activating lipid mediator class
switching between pro-inflammatory and pro-resolving mediators
[44,45]. Here, RvD1 has a net anti-inflammatory effect, perhaps
because its pro-inflammatory effects are suppressed by RvD1,
while its pro-resolving effects are replaced by exogenous RvD1.
Cigarette smoking causes both acute and chronic lung
inflammation with prominent involvement of neutrophils. Neu-
trophilic airway inflammation is one of the key underlying
pathophysiological processes in the development of COPD [46].
Recently, it was shown that cigarette smoke disrupts the normal
resolution of neutrophilic lung inflammation by reducing neutro-
phil apoptosis and efferocytosis [47]. Impairment of neutrophil
clearance can lead to irreversible local tissue damage via
production of mediators including neutrophil elastase and reactive
oxygen species [48]. Here we report that RvD1 dampens
neutrophil recruitment and enhances neutrophil clearance in
acute CS-induced inflammation. These results suggest that RvD1
or 17R-RvD1 might be useful as therapies to reduce chronic
inflammation and lung injury in diseases of chronic smoke
exposure such as COPD.
Alternatively activated or type II macrophages (M2) are
immunoregulatory cells that possess anti-inflammatory properties
and eliminate tissue debris and apoptotic bodies via phagocytosis.
Previous reports have shown that RvE1 and RvD2 enhanced
macrophage phagocytosis of bacterial ligands and apoptotic
neutrophils in sepsis and asthma models [49,50]. Here we show
that RvD1 promotes differentiation of pro-resolving macrophages
that have enhanced phagocytic activity in vitro and in vivo (Figure 7
and 8). It was recently reported that RvD1 regulates pro- and anti-
inflammatory micro RNAs via signaling through its G-protein
receptors ALX and GPR32, resulting in increased production of
IL-10 and decreased NF-kB activity [51]. Additionally, it is known
that IL-10 promotes the M2 phenotype [14,16]. These results,
combined with our findings that IL-10 is elevated in RvD1-treated
lungs (Figure 5H) and alveolar macrophages (Figure 8D), demon-
strate that RvD1 and IL-10 enhance M2 polarization by a positive
feedback mechanism initiated by RvD1-mediated G-protein
signaling.
Although neutrophil chemokines (MIP-2, KC) and broad-
spectrum pro-inflammatory signals (IL-1b, IL-6) were strongly
inhibited by RvD1, the macrophage chemoattractant MCP-1,
which was also induced by CS, was not reduced by RvD1 in
mouse lung. Interestingly, it has been reported that MCP-1
enhances efferocytosis by alveolar macrophages, and that MCP-1
is important for the resolution of inflammation [52]. This is
consistent with our observations that macrophage numbers were
not reduced by RvD1 and that RvD1 enhances efferocytosis
(Figure 7). RvD1 also up-regulated production of IL-10, a potent
immunoregulatory cytokine that is reported to be essential for the
resolution of lung inflammation [53] and which is significantly
decreased in sputum samples from COPD patients [54,55]. Taken
together, this suggests that RvD1 is not an indiscriminate anti-
inflammatory agent, but rather selectively activates specific anti-
inflammatory and pro-resolving pathways that include inhibition
Figure 7. RvD1 enhances macrophage phagocytosis in vivo and ex vivo. Mice were exposed to air or CS with or without RvD1 as described.
Lungs were digested and macrophages were isolated as described in Methods. The percentage of F4/80/Gr-1 double positive cells was quantified by
flow cytometry. (A) Dot plots shown are from one vehicle control mouse and two RvD1-treated mice. (B) BAL cells were harvested from naı ¨ve mice
and incubated ex vivo with 1 ng/ml IL-1b and 100 nM RvD1 for 30 minutes prior to the addition of FITC-labeled latex beads. Percentage of F4/80
+
macrophages that ingested FITC-latex beads was quantified by flow cytometry. Representative histogram of one out of 6 mice is shown. (C) Mean 6
SEM is shown for 6 animals from two independent experiments. *p,0.05, **p,0.01, ***p,0.001, Student’s t-test.
doi:10.1371/journal.pone.0058258.g007
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inflammatory, pro-resolving macrophages.
Smoking-related inflammation of the lungs, cardiovascular
system and other organs persists for months or even years after
smoking cessation, and COPD not only persists but also may
continue to worsen [1,2]. This suggests that development of novel
therapeutics should be focused on promoting resolution, rather
than preventing inflammation. Here, a single dose of 17R-RvD1
given after the final smoke exposure resulted in accelerated
reduction in BAL neutrophils and IL-6 (Figure 6). The pro-
resolving activity was maintained for at least 3 days, with
continued reductions in neutrophils and key pro-inflammatory
mediators. These results are similar to results recently reported
from Dr. Serhan’s laboratory that RvD1 and 17R-RvD1
accelerated the resolution of allergic airway inflammation in the
mouse ovalbumin model [25]. 17R-RvD1 is an alternate epimer of
RvD1 produced endogenously in the presence of aspirin, which
acetylates the COX-2 resulting in a shift from the 17S to the 17R
epimer [21]. The 17S epimer is subject to rapid inactivation by the
endogenous enzyme 15-prostaglandin dehydrogenase/eicosanoid
oxidoreductase (15-PGDH) whereas the 17R epimer is not. While
RvD1 was effective at inhibiting inflammation when given
immediately prior to smoke exposure, we were concerned that it
may not have a long enough half-life to be effective at promoting
resolution when given after smoke exposure. 17R-RvD1 has
similar biological activity and uses the same receptors [21] but is
Figure 8. RvD1 drives polarization of alternatively activated macrophages. Mice were exposed to air or CS with or without RvD1 as
described. (A) Expression of Arg-1 was measured in whole lung homogenates by Western blotting. Each lane represents one animal. B–F: Alveolar
macrophages were enriched from BAL cells by adherence and total RNA was extracted and subjected to quantitative RT-PCR to measure mRNA levels
of Arg1 (B), Mrc1 (C), IL-10 (D), iNOS (E) and TNFa (F). Mean 6 SEM is shown, normalized to 18S rRNA. Each group n=6 for Arg1, Mrc1 and IL-10; n=3
for iNOS and TNFa.
#P,0.05,
##P,0.01, compared to Vehicle/Air animal by one-way ANOVA with Bonferroni post-tests; *P,0.05, **P,0.01,
***P,0.001 versus Vehicle/Smoke animal by two-way ANOVA with Bonferroni post-test. {P,0.05 between RvD1/Air and RvD1/Smoke, ANOVA.
doi:10.1371/journal.pone.0058258.g008
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also possible that 17R-RvD1 would have been more efficacious
than RvD1 in the pre-treatment model (Figures 3, 4, 5), although
this has not been tested.
Cigarette smoke is a direct cause of several devastating diseases
including COPD for which there are few effective therapeutic
agents. Long-term use of glucocorticoids carries risks of infection
and other adverse effects potentially outweighing their benefits
[56], and many long-term smokers and emphysema patients
exhibit steroid resistance [57]. By blocking utilization of
arachidonic acid, COX-2 inhibitors not only block pro-inflam-
matory signals, but also inhibit resolvin biosynthesis [58].
Resolvins offer significant clinical potential because they promote
resolution and repair without being immunosuppressive. Here, we
have demonstrated that RvD1 possesses potent anti-inflammatory
and pro-resolving activity in vivo and in vitro. Inhalation therapy
with RvD1 may offer an alternative approach for treating human
inflammatory lung diseases including chronic lung injury and
COPD resulting from cigarette smoking and other chronic
injuries.
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